CytoReason Expands Its Reach in Asia, Forging Commercial Alliance with Helixrus to Leverage Machine Learning in Drug Development for Korean Drugmakers

CytoReason, a leading developer of computational disease models for efficient drug discovery and development, announced the signing of a commercial partnership with Helixrus, a leading Korean company focused on biological big data and multi-omics. The partnership will see Helixrus represent CytoReason’s unique AI platform and professional services in the Korean market.

CytoReason has established itself as a global leader in computational modeling of human diseases. The company’s multidisciplinary team of 65 leading biologists, bioinformaticians and data engineers has developed a technology that enables pharma and biotech companies to speed up drug R&D and bring novel therapies to the patients who most need them.

Recommended AI News: Veriff Enhances Face Match with New Authentication Capabilities

The alliance will focus on leveraging Helixrus’ deep knowledge of the Korean pharmaceutical market, and extensive network of relationships in Asian markets, to highlight CytoReason’s capabilities in prioritizing new targets, finding biomarkers, profiling combinations, stratifying patients, and other use cases within the drug lifecycle.

CytoReason has existing collaborations with five of the world’s largest pharmaceutical companies, including Pfizer and Sanofi. Its proprietary platform has yielded a range of clinically validated results in multiple diseases.

Recommended AI News: Syzygy Integration Releases iTAK in the App Store, a Cutting-Edge Situational Awareness App

“We’re thrilled to enter the Korean market with such an important player in South Korea’s pharmaceutical industry,” said David Harel, CEO and Co-founder of CytoReason. “Through this collaboration and others in Asian markets, our goal is to establish our computational disease models and professional services as the gold standard for drug discovery, development and portfolio management.”

“We are very excited to partner with CytoReason as they expand their footprint into Korea,” said Nick Choe, CEO of Helixrus, Inc. “CytoReason offers a unique AI drug discovery platform that already benefits a number of pharmaceutical companies worldwide, and we look forward to working together to improve drug discovery and development in Korea as well.”

Recommended AI News: Microsoft Industry Cloud Could Be a Worthwhile Consideration, According to Info-Tech Research Group

[To share your insights with us, please write to sghosh@martechseries.com]